Developer docs
API playgroundTry for free, no card

Search company profiles

Auris Health

Full company profile

uuid0003m6c

Namestring
Auris Health
Legal namestring
Auris Health Inc.
Websiteurl
aurishealth.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Auris Health, founded in 2007 and headquartered in Redwood City, California, is a medical robotics company that operates as a wholly-owned subsidiary of Johnson & Johnson MedTech following J&J's $3.4 billion acquisition in 2019. The company develops the MONARCH Platform, the first FDA-cleared flexible, robotically-assisted bronchoscopy system designed to provide physicians with access to and continuous visualization of patient airways to enable biopsy of suspicious lung nodules. The platform uses AI-powered navigation algorithms, an independently articulating telescoping scope and sheath, and an integrated camera for real-time visualization, enabling reach into all eighteen lung segments and approximately 48% of nodules located in the peripheral third of the lung that are inaccessible to conventional bronchoscopy. The enhanced MONARCH QUEST variant launched in 2025 adds more powerful AI navigation and integrates with GE HealthCare OEC 3D and Siemens Healthineers Cios Spin intraoperative imaging systems for 3D tool-in-lesion confirmation.

The company's revenue model combines one-time capital equipment sales of the MONARCH system to hospitals and healthcare systems with recurring per-procedure revenue from single-use consumables and biopsy accessories. Products are distributed exclusively through J&J MedTech's direct enterprise field sales force, targeting tertiary and quaternary hospitals performing interventional pulmonology and thoracic surgery procedures, with clinical evidence (including the BENEFIT and TARGET trials) and physician education as the primary demand-generation channels. The platform has received regulatory clearance in the United States and China, and was previously supported by more than $733 million in pre-acquisition equity funding across multiple rounds from investors including Lux Capital, Mithril Capital, Coatue, Partner Fund Management, and Viking Global Investors. The company has also been an active participant in IP litigation, including a Federal Circuit ruling reviving its challenge against Intuitive Surgical's robotic surgery patent.

Short descriptiontext

Auris Health, a Johnson & Johnson MedTech subsidiary, develops the MONARCH robotic-assisted bronchoscopy platform with AI-powered navigation for peripheral lung nodule biopsy, serving tertiary hospitals and interventional pulmonologists in the United States and China.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
robotic bronchoscopy systems, surgical robotics platforms, lung cancer diagnostics, minimally invasive biopsy, robotic medical devices
Industry3 codes
1Surgical Robotics & Computer-Assisted Surgery Platforms
CodeHLAHADAFPrimaryYes
2Bronchoscopy & Interventional Pulmonology
CodeHLAKANAJPrimaryNo
3Healthcare & Assistive Robotics
CodeHDAAAIACPrimaryNo
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Robotic-Assisted Bronchoscopy Systems
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Capital Equipment Sales
TypeHardware Sales
Description

The MONARCH Platform is sold as a capital medical device to hospitals and healthcare systems. Revenue is generated from the initial sale and installation of the robotic bronchoscopy system, representing a high-value one-time capital transaction typical of surgical robotics platforms.

intuitionlabs.ai
2Procedure-Based Consumables & Accessories
TypeUsage Based
Description

Recurring revenue from single-use accessories and consumables used in each MONARCH-guided bronchoscopy procedure, including biopsy needles and other interventional tools. Generates recurring per-procedure revenue tied to procedure volume.

jnjmedtech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1MONARCH Platform
Description

The first flexible, robotically assisted platform for bronchoscopy, providing access to and visualization of airways to enable healthcare providers to biopsy suspicious lung nodules. Now marketed under Johnson & Johnson MedTech.

jnjmedtech.com
Core offering1 text field

Auris Health develops and sells the MONARCH Platform, the first flexible, robotically assisted bronchoscopy system that enables physicians to access, visualize, and biopsy suspicious peripheral lung nodules. The enhanced MONARCH QUEST variant adds more powerful AI-powered navigation algorithms and integration with GE HealthCare OEC 3D and Siemens Cios Spin intraoperative imaging systems for tool-in-lesion confirmation. The system is sold as capital equipment to hospitals and healthcare systems, with recurring revenue from per-procedure consumables.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 48% of lung nodules are located in the peripheral third of the lung, requiring reach beyond conventional bronchoscopy capabilities
+2 more records
Product overview1 text field

Auris Health, now part of Johnson & Johnson MedTech, offers the MONARCH Platform—a robotic-assisted bronchoscopy system for minimally invasive lung nodule biopsy. The platform consists of the core MONARCH Platform and its enhanced variant MONARCH QUEST, which features advanced AI-powered navigation algorithms and integrates with major medical imaging systems (GE Health Care OEC 3D, Siemens Cios Spin). The technology enables physicians to access and visualize airways, reach peripheral lung lesions, and perform biopsies with continuous real-time visualization.

Product and service2 records
1MONARCH Platform
CategoryRobotic-Assisted Bronchoscopy Systems
Description

The MONARCH Platform is the first FDA-cleared flexible, robotically assisted bronchoscopy system. It provides access to and visualization of patient airways to enable healthcare providers to biopsy suspicious lung nodules. The system features AI-powered navigation algorithms, continuous intraoperative visualization via an integrated camera, and independently articulating telescoping scope and sheath that can reach all 18 lung segments to access small peripheral lesions with median lesion size of 18.5 mm. It is sold as capital equipment to tertiary and quaternary hospitals and healthcare systems through J&J MedTech's direct enterprise sales organization.

2MONARCH QUEST
CategoryRobotic-Assisted Bronchoscopy Systems
Description

MONARCH QUEST is the enhanced version of the MONARCH Platform, featuring more powerful AI-powered algorithms for navigation and image processing, with integration capabilities for GE HealthCare OEC 3D and Siemens Cios Spin intraoperative imaging systems. The imaging integration offers an easy-to-use workflow designed to improve targeting accuracy and tool-in-lesion confirmation during biopsy procedures. The advanced AI algorithm generates an airway map that extends further into the periphery of the lungs, improving access to hard-to-reach peripheral lung nodules for interventional pulmonologists and thoracic surgeons.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-01
Description

GE HealthCare's OEC 3D imaging system is integrated with the MONARCH Platform for robotic-assisted bronchoscopy. The imaging integration offers an easy-to-use workflow designed to improve targeting accuracy and enable tool-in-lesion confirmation during procedures, providing 3D intraoperative imaging guidance within the MONARCH bronchoscopy workflow.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-01
Description

Siemens Healthineers' Cios Spin intraoperative C-arm imaging system is integrated with the MONARCH Platform for robotic-assisted bronchoscopy. This integration enables 3D imaging and tool-in-lesion confirmation to improve targeting accuracy during biopsy procedures, complementing the AI-powered navigation capabilities of the MONARCH system.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Siemens Healthineers is the manufacturer of the Cios Spin intraoperative imaging system integrated with MONARCH; comparable as a technology integration partner providing intraoperative 3D imaging within the robotic bronchoscopy workflow.

TypeEmerging player
Description

Vicarious Surgical is an emerging surgical robotics company developing a virtual-reality-enabled robotic platform; comparable as a peer surgical robotics innovator competing for capital and hospital mindshare in robotic-assisted procedures.

TypeEmerging player
Description

Noah Medical develops the Galaxy System, a robotic bronchoscopy platform targeting the same peripheral lung nodule biopsy market as MONARCH, representing an emerging direct competitor with focused single-product specialization.

TypeBroad incumbent
Description

J&J is Auris Health's parent company and operates the broader MedTech portfolio including MONARCH; it is comparable as the owner and commercialization vehicle for the MONARCH Platform with global MedTech sales reach.

TypeBroad incumbent
Description

Stryker operates the Mako robotic surgery platform broadly across orthopedics and is expanding robotic applications; as a diversified surgical robotics incumbent, it represents a comparable capital medical device robotics business model.

TypeOthers
Description

GE HealthCare manufactures the OEC 3D imaging system integrated with MONARCH; comparable as a technology integration partner providing intraoperative 3D imaging for the robotic bronchoscopy procedure workflow.

TypeDirect peer
Description

Intuitive Surgical is the dominant surgical robotics company and a direct competitor in robotic bronchoscopy with its Ion platform, targeting the same peripheral lung nodule biopsy use case with a comparable robotic catheter system.

TypeEmerging player
Description

Asensus Surgical (formerly TransEnterix) develops the Senhance surgical system, an emerging robotic-assisted surgery platform with comparable capital medical device economics and hospital sales motion.

TypeBroad incumbent
Description

Medtronic is a broad MedTech incumbent with endoscopy and bronchoscopy products (including prior robotic-assisted platforms) and significant respiratory diagnostics presence, competing in adjacent interventional pulmonology procedure categories.

TypeDirect peer
Description

Pulmonx develops endoscopic lung diagnostic and therapeutic devices (Zephyr valves) for interventional pulmonology; comparable as a peer operating in the same physician specialty and bronchoscopy suite workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Auris Health

Robotic-Assisted Bronchoscopy Systemsaurishealth.com

Auris Health, a Johnson & Johnson MedTech subsidiary, develops the MONARCH robotic-assisted bronchoscopy platform with AI-powered navigation for peripheral lung nodule biopsy, serving tertiary hospitals and interventional pulmonologists in the United States and China.

What Auris Health does

Auris Health, founded in 2007 and headquartered in Redwood City, California, is a medical robotics company that operates as a wholly-owned subsidiary of Johnson & Johnson MedTech following J&J's $3.4 billion acquisition in 2019. The company develops the MONARCH Platform, the first FDA-cleared flexible, robotically-assisted bronchoscopy system designed to provide physicians with access to and continuous visualization of patient airways to enable biopsy of suspicious lung nodules. The platform uses AI-powered navigation algorithms, an independently articulating telescoping scope and sheath, and an integrated camera for real-time visualization, enabling reach into all eighteen lung segments and approximately 48% of nodules located in the peripheral third of the lung that are inaccessible to conventional bronchoscopy. The enhanced MONARCH QUEST variant launched in 2025 adds more powerful AI navigation and integrates with GE HealthCare OEC 3D and Siemens Healthineers Cios Spin intraoperative imaging systems for 3D tool-in-lesion confirmation.

The company's revenue model combines one-time capital equipment sales of the MONARCH system to hospitals and healthcare systems with recurring per-procedure revenue from single-use consumables and biopsy accessories. Products are distributed exclusively through J&J MedTech's direct enterprise field sales force, targeting tertiary and quaternary hospitals performing interventional pulmonology and thoracic surgery procedures, with clinical evidence (including the BENEFIT and TARGET trials) and physician education as the primary demand-generation channels. The platform has received regulatory clearance in the United States and China, and was previously supported by more than $733 million in pre-acquisition equity funding across multiple rounds from investors including Lux Capital, Mithril Capital, Coatue, Partner Fund Management, and Viking Global Investors. The company has also been an active participant in IP litigation, including a Federal Circuit ruling reviving its challenge against Intuitive Surgical's robotic surgery patent.

Auris Health firmographics

Firmographics
Name
Auris Health
Legal name
Auris Health Inc.
Website
https://aurishealth.com
Company type
Private
Founded year
2007
Operating status
Acquired
Headcount range
101–250 employees
Short description
Auris Health, a Johnson & Johnson MedTech subsidiary, develops the MONARCH robotic-assisted bronchoscopy platform with AI-powered navigation for peripheral lung nodule biopsy, serving tertiary hospitals and interventional pulmonologists in the United States and China.
Ownership category
akta.pro rank

Auris Health industry classification

Industry
Product category
Robotic-Assisted Bronchoscopy Systems
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
akta.pro secondary industries
Bronchoscopy & Interventional Pulmonology (HLAKANAJ), Healthcare & Assistive Robotics (HDAAAIAC)

Keywords

  • Robotic bronchoscopy systems
  • Surgical robotics platforms
  • Lung cancer diagnostics
  • Minimally invasive biopsy
  • Robotic medical devices

Where Auris Health is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Markets served

Auris Health business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Capital Equipment Sales: The MONARCH Platform is sold as a capital medical device to hospitals and healthcare systems. Revenue is generated from the initial sale and installation of the robotic bronchoscopy system, representing a high-value one-time capital transaction typical of surgical robotics platforms.
  2. Procedure-Based Consumables & Accessories: Recurring revenue from single-use accessories and consumables used in each MONARCH-guided bronchoscopy procedure, including biopsy needles and other interventional tools. Generates recurring per-procedure revenue tied to procedure volume.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Auris Health product offering

Product offering

Core offering

Auris Health develops and sells the MONARCH Platform, the first flexible, robotically assisted bronchoscopy system that enables physicians to access, visualize, and biopsy suspicious peripheral lung nodules. The enhanced MONARCH QUEST variant adds more powerful AI-powered navigation algorithms and integration with GE HealthCare OEC 3D and Siemens Cios Spin intraoperative imaging systems for tool-in-lesion confirmation. The system is sold as capital equipment to hospitals and healthcare systems, with recurring revenue from per-procedure consumables.

Product overview

Auris Health, now part of Johnson & Johnson MedTech, offers the MONARCH Platform—a robotic-assisted bronchoscopy system for minimally invasive lung nodule biopsy. The platform consists of the core MONARCH Platform and its enhanced variant MONARCH QUEST, which features advanced AI-powered navigation algorithms and integrates with major medical imaging systems (GE Health Care OEC 3D, Siemens Cios Spin). The technology enables physicians to access and visualize airways, reach peripheral lung lesions, and perform biopsies with continuous real-time visualization.

Differentiator

Problem solved

Functional benefit

Brands

  • MONARCH Platform: The first flexible, robotically assisted platform for bronchoscopy, providing access to and visualization of airways to enable healthcare providers to biopsy suspicious lung nodules. Now marketed under Johnson & Johnson MedTech.

Products and services

  • MONARCH Platform The MONARCH Platform is the first FDA-cleared flexible, robotically assisted bronchoscopy system. It provides access to and visualization of patient airways to enable healthcare providers to biopsy suspicious lung nodules. The system features AI-powered navigation algorithms, continuous intraoperative visualization via an integrated camera, and independently articulating telescoping scope and sheath that can reach all 18 lung segments to access small peripheral lesions with median lesion size of 18.5 mm. It is sold as capital equipment to tertiary and quaternary hospitals and healthcare systems through J&J MedTech's direct enterprise sales organization.
  • MONARCH QUEST MONARCH QUEST is the enhanced version of the MONARCH Platform, featuring more powerful AI-powered algorithms for navigation and image processing, with integration capabilities for GE HealthCare OEC 3D and Siemens Cios Spin intraoperative imaging systems. The imaging integration offers an easy-to-use workflow designed to improve targeting accuracy and tool-in-lesion confirmation during biopsy procedures. The advanced AI algorithm generates an airway map that extends further into the periphery of the lungs, improving access to hard-to-reach peripheral lung nodules for interventional pulmonologists and thoracic surgeons.

Quantifiable outcome

  • 48% of lung nodules are located in the peripheral third of the lung, requiring reach beyond conventional bronchoscopy capabilities
  • +2 more outcomes

Companies that use Auris Health

Customer profile

Segments2 records

Ideal customer profiles1 record

Auris Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Auris Health partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • GE HealthCarecoreTechnology or Integration · 1 May 2025GE HealthCare's OEC 3D imaging system is integrated with the MONARCH Platform for robotic-assisted bronchoscopy. The imaging integration offers an easy-to-use workflow designed to improve targeting accuracy and enable tool-in-lesion confirmation during procedures, providing 3D intraoperative imaging guidance within the MONARCH bronchoscopy workflow.
  • Siemens HealthineerscoreTechnology or Integration · 1 May 2025Siemens Healthineers' Cios Spin intraoperative C-arm imaging system is integrated with the MONARCH Platform for robotic-assisted bronchoscopy. This integration enables 3D imaging and tool-in-lesion confirmation to improve targeting accuracy during biopsy procedures, complementing the AI-powered navigation capabilities of the MONARCH system.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Auris Health competitors and assessment

Company assessment

Others

  • Siemens Healthineers: Siemens Healthineers is the manufacturer of the Cios Spin intraoperative imaging system integrated with MONARCH; comparable as a technology integration partner providing intraoperative 3D imaging within the robotic bronchoscopy workflow.
  • GE HealthCare: GE HealthCare manufactures the OEC 3D imaging system integrated with MONARCH; comparable as a technology integration partner providing intraoperative 3D imaging for the robotic bronchoscopy procedure workflow.

Emerging players

  • Vicarious Surgical: Vicarious Surgical is an emerging surgical robotics company developing a virtual-reality-enabled robotic platform; comparable as a peer surgical robotics innovator competing for capital and hospital mindshare in robotic-assisted procedures.
  • Noah Medical: Noah Medical develops the Galaxy System, a robotic bronchoscopy platform targeting the same peripheral lung nodule biopsy market as MONARCH, representing an emerging direct competitor with focused single-product specialization.
  • Asensus Surgical: Asensus Surgical (formerly TransEnterix) develops the Senhance surgical system, an emerging robotic-assisted surgery platform with comparable capital medical device economics and hospital sales motion.

Broad incumbents

  • Johnson & Johnson: J&J is Auris Health's parent company and operates the broader MedTech portfolio including MONARCH; it is comparable as the owner and commercialization vehicle for the MONARCH Platform with global MedTech sales reach.
  • Stryker: Stryker operates the Mako robotic surgery platform broadly across orthopedics and is expanding robotic applications; as a diversified surgical robotics incumbent, it represents a comparable capital medical device robotics business model.
  • Medtronic: Medtronic is a broad MedTech incumbent with endoscopy and bronchoscopy products (including prior robotic-assisted platforms) and significant respiratory diagnostics presence, competing in adjacent interventional pulmonology procedure categories.

Direct peers

  • Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics company and a direct competitor in robotic bronchoscopy with its Ion platform, targeting the same peripheral lung nodule biopsy use case with a comparable robotic catheter system.
  • Pulmonx: Pulmonx develops endoscopic lung diagnostic and therapeutic devices (Zephyr valves) for interventional pulmonology; comparable as a peer operating in the same physician specialty and bronchoscopy suite workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Auris Health social profiles

Digital presence

Auris Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Auris Health leadership team

Management profile

Number of profiles

Profiles2 records

Auris Health funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Auris Health M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auris Health

What does Auris Health do?

Auris Health develops and sells the MONARCH Platform, the first flexible, robotically assisted bronchoscopy system that enables physicians to access, visualize, and biopsy suspicious peripheral lung nodules. The enhanced MONARCH QUEST variant adds more powerful AI-powered navigation algorithms and integration with GE HealthCare OEC 3D and Siemens Cios Spin intraoperative imaging systems for tool-in-lesion confirmation. The system is sold as capital equipment to hospitals and healthcare systems, with recurring revenue from per-procedure consumables.

Is Auris Health a public or private company?

Auris Health is a private company. It is classified as corporate owned and is currently acquired.

When was Auris Health founded?

Auris Health was founded in 2007. It employs 101 to 250 people.

Where is Auris Health based?

Auris Health is headquartered in Redwood City, United States, in the North America region.

How does Auris Health make money?

Two revenue lines are on record. Capital Equipment Sales are the primary driver. The others are procedure-Based Consumables & Accessories.

Who are Auris Health's main competitors?

Others on record are Siemens Healthineers and GE HealthCare. Emerging players are Vicarious Surgical, Noah Medical and Asensus Surgical. Broad incumbents are Johnson & Johnson, Stryker and Medtronic. Direct peers are Intuitive Surgical and Pulmonx.

Does Auris Health have an API?

No public API is recorded for Auris Health.

What industry is Auris Health in?

Auris Health's product category is Robotic-Assisted Bronchoscopy Systems. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAKANAJ, Bronchoscopy & Interventional Pulmonology. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaHansen MedicalHansen Medical, founded in 2002 by Frederic Moll, designs medical robotics for catheter-based procedures, including the Magellan and Sensei systems. It went public in 2006, raising $75 million, and was acquired by Auris Surgical Robotics in 2016 for $80 million.Bloomberg Law NewsJ&J Ruling Offers Path for Deferred-Payment M&A Deals Gone BadDelaware's Supreme Court upheld most of a $1 billion judgment against Johnson & Johnson, reducing it to $811 million, finding the healthcare giant tricked Auris Health Inc. into a $3.4 billion acquisition and broke promises to prioritize approvals for Auris' flagship product while rejecting $300 million in additional claims related to the iPlatform surgical robot system. The ruling sets precedent for deferred-payment M&A deals by restricting the use of implied covenant claims in earnout disputes, effectively requiring contracts to address foreseeable developments explicitly. The decision leaves $2.35 billion in earnout payments still at stake and signals that such litigation will continue as founders and acquirers take divergent approaches to post-transaction valuation.MccarthyGood Faith in M&A Deals at the Supreme Court of Delaware: A Canadian PerspectiveThe Supreme Court of Delaware issued a January 12, 2026 decision in Johnson & Johnson v. Fortis Advisors LLC reversing the Court of Chancery on the implied covenant of good faith in a post-closing earnout dispute arising from J&J's $3.4 billion acquisition of medical robotics company Auris Health, finding the covenant could not fill a contractual gap when the merger agreement explicitly specified 510(k) regulatory clearance requirements. The court affirmed the lower court's $1 billion+ damages award for breach of contract and fraud, but rejected the use of the implied covenant to require J&J to pursue alternative De Novo regulatory review pathways. The article analyzes the decision through a Canadian legal lens, noting that Canadian courts similarly resist using good faith duties to alter post-closing regulatory obligations in heavily negotiated commercial agreements between sophisticated parties.BenzingaCourt Orders Recalculation Of Damages In Johnson & Johnson Auris Case - Johnson & Johnson (NYSE:JNJ)The Delaware Supreme Court partially overturned a $1 billion damages award against Johnson & Johnson, unanimously ruling that the lower court erred in finding J&J had an implied obligation to secure regulatory approval for an iPlatform product by end of 2021. The court upheld most other findings that Johnson & Johnson breached its contract with Auris Health, failed to honor post-acquisition commitments, and committed fraud related to a regulatory investigation, leaving the case to be remanded for damages recalculation that could reduce the award by a couple hundred million dollars. Johnson & Johnson stated it is reviewing its options following the decision.Mobility ForesightsNorth America Robotic Endoscopy Device Market Size and Forecasts 2031The North America robotic endoscopy device market is projected to grow from USD 1.98 billion in 2025 to USD 4.23 billion by 2031, at a compound annual growth rate of 13.6%. Key drivers include rising demand for minimally invasive procedures, increasing gastrointestinal and pulmonary disease prevalence, and technological advancements in AI-guided navigation, 3D imaging, and capsule robotics. Major players such as Intuitive Surgical, Medtronic, Johnson & Johnson's Auris Health, Olympus Corporation, and Medrobotics are advancing robotic bronchoscopy, colonoscopy, and capsule endoscopy platforms across North American hospitals and specialty clinics.IntuitionLabsSF Bay Area Medtech: An Analysis of 1,000+ CompaniesA comprehensive industry analysis identifies the San Francisco Bay Area as one of the United States' most concentrated medical device clusters, hosting over 1,028 medtech organizations and employing approximately 147,000 people in the life sciences sector, with California accounting for roughly a quarter of total U.S. medtech revenue. The region has attracted over $51 billion in venture capital funding for life sciences during 2019–2024, driven by major players including Intuitive Surgical ($2.04 billion Q3 2024 revenue), Penumbra ($1.06 billion FY2023 revenue), and a surge of AI-driven startups across robotics, diagnostics, and remote monitoring. Notable M&A activity includes Johnson & Johnson's $12.5 billion acquisition of Shockwave Medical and its $3.4 billion purchase of Auris Health, underscoring the Bay Area's role as a global medtech innovation hub.Bloomberg Law NewsJ&J’s Billion-Dollar Appeal Aims Spotlight at ‘Litigation Trap’Johnson & Johnson is appealing to Delaware's Supreme Court to overturn a record $1 billion court judgment stemming from its $3.4 billion acquisition of Auris Health Inc., where a lower court found the company liable for breaching a pledge to prioritize a surgical robot platform it acquired. The case is part of a broader wave of earnout litigation flooding Delaware's business tribunal, with other recent rulings including a $181 million judgment against an AstraZeneca affiliate and a $50 million loss by Arthur J. Gallagher & Co. Legal experts note that earnout provisions—designed to bridge valuation gaps in deals—are increasingly being described as "litigation traps," as they create perverse incentives and often result in court battles when buyers and sellers disagree on milestone performance.TracxnTop Companies in Endoscopy Devices (Oct, 2025)The article presents a ranked list of top startups in the endoscopy devices sector, highlighting companies such as Auris Health, Pentax Medical, EvoEndo, and Wooptix. It details their founding years, funding stages, total capital raised, and specific technological focuses within the medical imaging field. The report also notes that an average of three new companies in this niche have been launched annually over the past decade.LegaladvantagePatents and IP Trends Transforming the Automotive IndustryThe Federal Circuit revived Auris Health's challenge against Intuitive Surgical Operations' robotic surgery patent, directing the PTAB to reassess the patent on obviousness grounds and potentially setting a precedent for high-tech medical device patents. The ruling challenges the use of "industry scepticism" as a defence in patent cases, which could reshape competitive dynamics in the surgical robotics sector and affect companies' ability to protect incremental innovations. The article also presents five-year patent filing data showing 10,550 total publications (2019-2023), with the US leading at 4,823 applications, followed by China (2,388) and the European Patent Office (1,939).